Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression

Marleen van de Beek1, Inger van Steenoven1, Jessica J van der Zande1

  • 1Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands.

Abstract

Insights

Prodromal dementia with Lewy bodies (MCI-LB) patients exhibit distinct cognitive and neuropsychiatric profiles compared to prodromal Alzheimer's disease (MCI-AD) patients, with MCI-LB showing faster attention decline. Early diagnosis is crucial as symptoms impact prodromal stages.

Area of Science:

  • Neurology
  • Neuroscience
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) can be a prodromal stage for dementia.
  • Distinguishing between subtypes of prodromal MCI is crucial for prognosis and management.
  • Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) are common causes of dementia, with distinct clinical features.

Purpose of the Study:

  • To compare clinical characteristics, cognitive decline, and predictors of dementia progression in patients with prodromal MCI due to DLB (MCI-LB) versus prodromal MCI due to AD (MCI-AD).
  • To identify factors associated with the time to dementia conversion in both MCI-LB and MCI-AD cohorts.

Main Methods:

  • A cohort study comparing 73 MCI-LB patients and 124 MCI-AD patients from the Amsterdam Dementia Cohort.
  • Evaluation of core DLB features, neuropsychiatric symptoms, caregiver burden, MRI, and CSF biomarkers.
  • Longitudinal assessment of cognitive function (memory, attention, executive functions, language, visuospatial) and time to dementia using linear mixed models and Cox proportional hazards regressions.

Main Results:

  • Parkinsonism was common in MCI-LB (69%). MCI-LB patients reported more neuropsychiatric symptoms and higher caregiver burden.
  • At baseline, MCI-LB patients had worse non-memory cognition, while MCI-AD patients had worse memory.
  • Over time, MCI-LB showed faster attention decline, whereas MCI-AD showed faster decline in overall cognition (MMSE) and memory. Predictors for faster dementia conversion differed between groups.

Conclusions:

  • MCI-LB patients present with unique neuropsychiatric and cognitive profiles, notably a faster decline in attention compared to MCI-AD patients.
  • These findings underscore the significance of early and accurate diagnosis in the prodromal stages of dementia, as symptoms manifest early and impact patients.
  • Distinct predictors for dementia progression highlight the need for tailored diagnostic and therapeutic approaches for MCI-LB and MCI-AD.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
458
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
876
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
699